Visionweb & Neurolens Collaborate to Increase Prism Specificity

Through VisionWeb's ordering platform, prism can now be entered to the 1/100th prism diopter

Ongoing research from a myriad of sources has indicated that at least two out of three patients experience the symptoms of eye misalignment, and the rapid acceleration in remote working and learning over the past two years has undoubtedly led to a rise in this figure. Optical prisms are one of the most commonly employed treatment modalities to correct these binocular vision issues.

As such, technological innovations in this space will become increasingly important to the future of eyecare. In order to ensure that eyecare providers are able to meet these growing challenges, Neurolens and VisionWeb have worked together to expand the prism field from 1/4th prism diopter to 1/100th prism diopter when placing orders through VisionWeb’s ordering platform.

“At Neurolens, we strongly believe that the eyecare industry must evolve beyond visual acuity to own the visual comfort space as well,” says Pierre Bertrand, Chief Executive Officer of Neurolens. “A large and growing percentage of the population is suffering from the symptoms of binocular vision issues—some on a daily basis—and Neurolenses provide proven relief for these patients. We are proud to collaborate with an industry leader like VisionWeb to ensure that eyecare providers can prescribe optical prism to the specificity required to meet the needs of today’s patients.”

This expanded prism range will allow Neurolens providers to take advantage of the highly accurate measurements from the Neurolens Measurement Device (NMD) and Neurolens Measurement Device, Gen 2 (NMD2) and prescribe precise prism measurements for their patients. “We are learning more every day about how small amounts of prism can create tremendous symptom relief for patients,” says Vivek Labhishetty BSc Optometry, MSc, PhD, Director of Clinical Research for Neurolens. “This creates an imperative to ensure prism measurements can be entered with a high degree of specificity to maximize the number of patients that can be helped by this technology.”

Mike Bonacci, Director of Integrations at VisionWeb says, “We are on a mission to make it easier for people in the eyecare industry to do their jobs, and we will continue to pioneer technology that enables eyecare providers to more efficiently conduct business and meet the needs of their patients. This development sends yet another signal that VisionWeb will make every effort to remain on the forefront of emerging trends in practice management and patient care.”

SourceNeurolens

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.